HOF Capital

HOF Capital is a venture capital firm founded in 2016 and headquartered in New York, New York, with additional offices in London and Cairo. The firm specializes in investing in early-stage and later-stage start-ups, focusing primarily on technology sectors such as artificial intelligence, fintech, enterprise solutions, and biotechnology. HOF Capital aims to support entrepreneurs in developing innovative technologies that address significant social challenges. The firm invests in both B2B and B2B2C companies across various regions, including the United States, Canada, Western Europe, and Israel. With a commitment to partnering with ambitious entrepreneurs, HOF Capital plays a role in guiding companies from their initial ideas through to an initial public offering.

Hisham Elhaddad

Co-Founder and Managing Partner

Karim Fattal

COO

Sabrina Halper

Investor and Community Lead

Neha Manaktala

Venture Partner

Paul Quigley

Principal

Troy Shen

Senior Associate

Daniel Shin

Venture Partner

David Teten

Venture Partner

Victor Wang

Partner

Fady Yacoub

Co-Founder and Managing Partner

Mengyi Yuan

Venture Analyst

Past deals in Newfoundland

Sequence Bio

Seed Round in 2019
Sequence Bio is a biotechnology company focused on enhancing drug discovery and development by leveraging the genetic diversity found in isolated populations, particularly in Newfoundland. The company aims to improve the treatment of complex and inherited diseases through its genome therapy platform, which involves collecting DNA and health information from these unique populations. By understanding the genetic factors that contribute to disease, Sequence Bio seeks to identify better drug targets and create more effective medicines, ultimately addressing the high failure rate of drug candidates and expediting the delivery of much-needed therapies to patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.